Related references
Note: Only part of the references are listed.Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex
Keiko Ohoyama et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia: A Randomized, Double-blind, Risperidone-Compared Trial
Jaewon Yang et al.
CLINICAL NEUROPHARMACOLOGY (2010)
The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D-2 and anti-serotonin 5-HT2A activity
Hidenobu Suzuki et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2010)
The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study
Esther Garcia et al.
CNS DRUGS (2009)
Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent
T Ochi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Serotonin receptors : their key role in drugs to treat schizophrenia
HY Meltzer et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Share Paper
